Literature DB >> 20981441

Clinical characteristics of children with group A streptococcal toxic shock syndrome admitted to pediatric intensive care units.

Antonio Rodríguez-Nuñez1, Silvia Dosil-Gallardo, Iolanda Jordan.   

Abstract

UNLABELLED: Streptococcal toxic shock syndrome (STSS) is a very rare and severe form of group A streptococcal infection whose clinical characteristics, therapy, morbidity, and mortality in children are not well known. Our objective was to describe the clinical characteristics of STSS in a series of children admitted to pediatric intensive care units (PICU). A multicenter, retrospective study of children with STSS admitted to 14 PICUs between January 1998 and December 2009 was conducted. Clinical information was obtained retrospectively by chart review. Data from 41 children were collected, 90% corresponding to the second half of the study period. Initial symptoms and signs were nonspecific. All patients developed shock and organ dysfunction, 78.0% developed coagulopathy, 70.7% neurologic dysfunction, and 68.3% respiratory failure. Rapid pharyngeal test for Streptococcus was positive in 78.0%. Initial leukocyte count was quite variable, with leukopenia present in 51.2% of patients and leukocytosis in 31.7%. Children were treated with antibiotics against group A Streptococcus (GAS), usually G penicillin or cephalosporin plus clindamycin. After a median PICU stay of 7 days (range 0-41), 65.8% of patients survived, 26.8% with sequelae. The cause of death of the 11 non-survivors was refractory shock and multi-organ failure.
CONCLUSIONS: STSS is a very severe condition secondary to invasive GAS infection. It can occur at any age, but especially in young children. Due to the lack of specific symptoms and signs and its very rapid progression to shock and organ dysfunction, pediatricians and emergency physicians must be aware of this possibility and immediately initiate aggressive treatment when suspected.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20981441     DOI: 10.1007/s00431-010-1337-x

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  18 in total

Review 1.  Gram-positive toxic shock syndromes.

Authors:  Emma Lappin; Andrew J Ferguson
Journal:  Lancet Infect Dis       Date:  2009-05       Impact factor: 25.071

2.  [Streptococcal toxic shock syndrome: an emerging pathology?].

Authors:  S Dosil Gallardo; I Jordan Garcia; E Morteruel Arizcuren; A Rodríguez Nuñez
Journal:  An Pediatr (Barc)       Date:  2009-02-07       Impact factor: 1.500

3.  Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome--a comparative observational study. The Canadian Streptococcal Study Group.

Authors:  R Kaul; A McGeer; A Norrby-Teglund; M Kotb; B Schwartz; K O'Rourke; J Talbot; D E Low
Journal:  Clin Infect Dis       Date:  1999-04       Impact factor: 9.079

4.  Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. The Working Group on Severe Streptococcal Infections.

Authors: 
Journal:  JAMA       Date:  1993-01-20       Impact factor: 56.272

5.  [Lethal streptococcal toxic shock syndrome in pediatrics. Presentation of 3 cases].

Authors:  J M López Alvarez; M E Valerón Lemaur; E Consuegra Llapur; L Urquía Martí; A Morón Saén de Casas; R González Jorge
Journal:  Med Intensiva       Date:  2007-03       Impact factor: 2.491

6.  Morbidity and mortality of patients with invasive group A streptococcal infections admitted to the ICU.

Authors:  Sangeeta Mehta; Allison McGeer; Donald E Low; David Hallett; Dennis J Bowman; Stacey L Grossman; Thomas E Stewart
Journal:  Chest       Date:  2006-12       Impact factor: 9.410

7.  Clinical and epidemiological aspects of invasive Streptococcus pyogenes infections in Denmark during 2003 and 2004.

Authors:  Bogdan Luca-Harari; Kim Ekelund; Mark van der Linden; Margit Staum-Kaltoft; Anette M Hammerum; Aftab Jasir
Journal:  J Clin Microbiol       Date:  2007-10-24       Impact factor: 5.948

8.  Intravenous immunoglobulin in children with streptococcal toxic shock syndrome.

Authors:  Samir S Shah; Matthew Hall; Raj Srivastava; Anupama Subramony; James E Levin
Journal:  Clin Infect Dis       Date:  2009-11-01       Impact factor: 9.079

9.  Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial.

Authors:  Jessica Darenberg; Nahla Ihendyane; Jan Sjölin; Ewa Aufwerber; Sven Haidl; Per Follin; Jan Andersson; Anna Norrby-Teglund
Journal:  Clin Infect Dis       Date:  2003-07-17       Impact factor: 9.079

10.  Epidemiology of severe Streptococcus pyogenes disease in Europe.

Authors:  Theresa L Lamagni; Jessica Darenberg; Bogdan Luca-Harari; Tuula Siljander; Androulla Efstratiou; Birgitta Henriques-Normark; Jaana Vuopio-Varkila; Anne Bouvet; Roberta Creti; Kim Ekelund; Maria Koliou; Ralf René Reinert; Angeliki Stathi; Lenka Strakova; Vasilica Ungureanu; Claes Schalén; Aftab Jasir
Journal:  J Clin Microbiol       Date:  2008-05-07       Impact factor: 5.948

View more
  6 in total

Review 1.  Current insights in invasive group A streptococcal infections in pediatrics.

Authors:  Anne Filleron; Eric Jeziorski; Anne-Laure Michon; Michel Rodière; Hélène Marchandin
Journal:  Eur J Pediatr       Date:  2012-02-25       Impact factor: 3.183

2.  Streptococcal Toxic Shock syndrome.

Authors:  Vidya Krishna; Shuba Sankaranarayan; Rajakumar Padur Sivaraman; Krithika Prabaharan
Journal:  Indian J Pediatr       Date:  2013-12-03       Impact factor: 1.967

3.  Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012.

Authors:  R P Dellinger; Mitchell M Levy; Andrew Rhodes; Djillali Annane; Herwig Gerlach; Steven M Opal; Jonathan E Sevransky; Charles L Sprung; Ivor S Douglas; Roman Jaeschke; Tiffany M Osborn; Mark E Nunnally; Sean R Townsend; Konrad Reinhart; Ruth M Kleinpell; Derek C Angus; Clifford S Deutschman; Flavia R Machado; Gordon D Rubenfeld; Steven Webb; Richard J Beale; Jean-Louis Vincent; Rui Moreno
Journal:  Intensive Care Med       Date:  2013-01-30       Impact factor: 17.440

4.  Similarities and Differences Between Staphylococcal and Streptococcal Toxic Shock Syndromes in Children: Results From a 30-Case Cohort.

Authors:  Etienne Javouhey; Pierre-Adrien Bolze; Claire Jamen; Gerard Lina; Cédric Badiou; Claire Poyart; Aurelie Portefaix; Anne Tristan; Frédéric Laurent; Michèle Bes; François Vandenesch; Yves Gilletand; Olivier Dauwalder
Journal:  Front Pediatr       Date:  2018-11-28       Impact factor: 3.418

5.  Manifestations of Toxic Shock Syndrome in Children, Columbus, Ohio, USA, 2010-20171.

Authors:  Aliza Cook; Sarah Janse; Joshua R Watson; Guliz Erdem
Journal:  Emerg Infect Dis       Date:  2020-06       Impact factor: 6.883

6.  Carvacrol exhibits rapid bactericidal activity against Streptococcus pyogenes through cell membrane damage.

Authors:  Niluni M Wijesundara; Song F Lee; Zhenyu Cheng; Ross Davidson; H P Vasantha Rupasinghe
Journal:  Sci Rep       Date:  2021-01-15       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.